New York, Oct. 19, 2022 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report “Global Mesenchymal Stem Cells (MSC) Industry” – https://www.reportlinker.com/p05961465/?utm_source=GNW
Online interactive peer-to-peer collaborative bespoke updates
Access to our digital archives and MarketGlass Research Platform
Complimentary updates for one year
Global Mesenchymal Stem Cells (MSC) Market to Reach $6.5 Billion by 2027
Amid the COVID-19 crisis, the global market for Mesenchymal Stem Cells (MSC) estimated at US$3 Billion in the year 2020, is projected to reach a revised size of US$6.5 Billion by 2027, growing at a CAGR of 12% over the analysis period 2020-2027. Bone Marrow, one of the segments analyzed in the report, is projected to record a 13.1% CAGR and reach US$2.1 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Adipose Tissues segment is readjusted to a revised 14.8% CAGR for the next 7-year period.
The U.S. Market is Estimated at $868.1 Million, While China is Forecast to Grow at 11.4% CAGR
The Mesenchymal Stem Cells (MSC) market in the U.S. is estimated at US$868.1 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.1 Billion by the year 2027 trailing a CAGR of 11.4% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 10.2% and 10% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 8.3% CAGR.
Fetal Liver Segment to Record 11.4% CAGR
In the global Fetal Liver segment, USA, Canada, Japan, China and Europe will drive the 11.2% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$385.9 Million in the year 2020 will reach a projected size of US$810.3 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$770.3 Million by the year 2027.
Select Competitors (Total 56 Featured) –
Cell Applications Inc.
Celprogen Inc.
Cyagen US Inc.
Genlantis Inc.
Lonza Group
Mesoblast Limited
MilliporeSigma
Neuromics
Orthofix International N.V.
PromoCell GmbH
R&D Systems Inc.
ScienCell Research Laboratories
Stemcell Technologies Inc.
Stemedica Cell Technologies Inc.
Thermo Fischer Scientific Inc.
Read the full report: https://www.reportlinker.com/p05961465/?utm_source=GNW
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Mesenchymal Stem Cells Market on a Rapid Growth Path
Recent Market Activity
Current and Future Analysis
The Present and Future of MSC Therapies
Select MSC-based Therapeutics
Mesenchymal Stem Cell Research
Completed Phase III Studies with MSCs
MSCs are Being Explored for Several New Treatment Possibilities
Widespread Commercialization of ’Off-the-Shelf’ MSCs to Become
a Reality
Software Companies Endeavour to Cash in on the Boom
Mesenchymal Stem Cells (MSC) – Global Key Competitors
Percentage Market Share in 2022 (E)
Competitive Market Presence – Strong/Active/Niche/Trivial for
Players Worldwide in 2022 (E)
Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS
Cell Applications, Inc. (USA)
Celprogen, Inc. (USA)
Cyagen US Inc. (USA)
Genlantis, Inc. (USA)
Lonza Group (Switzerland)
Mesoblast Limited (Australia)
MilliporeSigma (USA)
Neuromics (USA)
Orthofix International N.V. (Italy)
PromoCell GmbH (Germany)
R&D Systems, Inc. (USA)
ScienCell Research Laboratories (USA)
Stemcell Technologies Inc. (Canada)
Stemedica Cell Technologies, Inc. (USA)
Thermo Fischer Scientific, Inc. (USA)
Vitro Biopharma (USA)
3. MARKET TRENDS & DRIVERS
Development of Regenerative Medicine Accelerates Demand for MSCs
Ageing Demographics to Drive Demand for Mesenchymal Stem Cell
Therapies
Global Aging Population Statistics – Opportunity Indicators
Growing Prevalence of Chronic Diseases Propels Demand for
Mesenchymal Stem Cells
Key Disease Statistics – Opportunity Indicators
Growing Volume of Orthopedic Procedures: An Opportunity for the
MSC Market
Adult Stem Cell Therapies on Growth Trajectory, as
Controversies Continue to Haunt Embryonic Stem Cell Research
Adult Stem Cells and Embryonic Stem Cells – A Comparison
MSCs Versus Embryonic or Induced Pluripotent Stem Cells
MSC Therapies – Immune to Ethical Issues Applicable to
Embryonic Stem Cells
MSCs – A Potential Vehicle for ’Targeted Drug Delivery’
Stem Cell Based Bone Grafts: Promising Growth Ahead
Loopholes Associated with In Vivo Properties Constrain
Therapeutic Advancements
Major Challenges Confronting Mesenchymal Stem Cell Market
Allogeneic MSCs – Offering Promise in Immunosuppressive and
Tissue Repair Therapy
Administration Route Determines the Effectiveness of MSCs
4. GLOBAL MARKET PERSPECTIVE
Table 1: World Recent Past, Current & Future Analysis for Other
Applications by Geographic Region – USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets – Independent
Analysis of Annual Sales in US$ Million for Years 2020 through
2027 and % CAGR
Table 2: World Historic Review for Other Applications by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets – Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR
Table 3: World 15-Year Perspective for Other Applications by
Geographic Region – Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2021 & 2027
Table 4: World Recent Past, Current & Future Analysis for
Mesenchymal Stem Cells (MSC) by Geographic Region – USA,
Canada, Japan, China, Europe, Asia-Pacific and Rest of World
Markets – Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR
Table 5: World Historic Review for Mesenchymal Stem Cells (MSC)
by Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets – Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR
Table 6: World 15-Year Perspective for Mesenchymal Stem Cells
(MSC) by Geographic Region – Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets for Years 2012, 2021 & 2027
Table 7: World Recent Past, Current & Future Analysis for Bone
Marrow by Geographic Region – USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets – Independent
Analysis of Annual Sales in US$ Million for Years 2020 through
2027 and % CAGR
Table 8: World Historic Review for Bone Marrow by Geographic
Region – USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets – Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR
Table 9: World 15-Year Perspective for Bone Marrow by
Geographic Region – Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2021 & 2027
Table 10: World Recent Past, Current & Future Analysis for
Adipose Tissues by Geographic Region – USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets –
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR
Table 11: World Historic Review for Adipose Tissues by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets – Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR
Table 12: World 15-Year Perspective for Adipose Tissues by
Geographic Region – Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2021 & 2027
Table 13: World Recent Past, Current & Future Analysis for
Fetal Liver by Geographic Region – USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets – Independent
Analysis of Annual Sales in US$ Million for Years 2020 through
2027 and % CAGR
Table 14: World Historic Review for Fetal Liver by Geographic
Region – USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets – Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR
Table 15: World 15-Year Perspective for Fetal Liver by
Geographic Region – Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2021 & 2027
Table 16: World Recent Past, Current & Future Analysis for Lung
by Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets – Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027 and
% CAGR
Table 17: World Historic Review for Lung by Geographic Region –
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World Markets – Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR
Table 18: World 15-Year Perspective for Lung by Geographic
Region – Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World for Years
2012, 2021 & 2027
Table 19: World Recent Past, Current & Future Analysis for Cord
Blood by Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets – Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027 and
% CAGR
Table 20: World Historic Review for Cord Blood by Geographic
Region – USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets – Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR
Table 21: World 15-Year Perspective for Cord Blood by
Geographic Region – Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2021 & 2027
Table 22: World Recent Past, Current & Future Analysis for
Other Sources of MSC Isolation by Geographic Region – USA,
Canada, Japan, China, Europe, Asia-Pacific and Rest of World
Markets – Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR
Table 23: World Historic Review for Other Sources of MSC
Isolation by Geographic Region – USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets – Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR
Table 24: World 15-Year Perspective for Other Sources of MSC
Isolation by Geographic Region – Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World for Years 2012, 2021 & 2027
Table 25: World Recent Past, Current & Future Analysis for
Disease Modelling by Geographic Region – USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets –
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR
Table 26: World Historic Review for Disease Modelling by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets – Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR
Table 27: World 15-Year Perspective for Disease Modelling by
Geographic Region – Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2021 & 2027
Table 28: World Recent Past, Current & Future Analysis for Drug
Development & Discovery by Geographic Region – USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World Markets –
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR
Table 29: World Historic Review for Drug Development &
Discovery by Geographic Region – USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets – Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR
Table 30: World 15-Year Perspective for Drug Development &
Discovery by Geographic Region – Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World for Years 2012, 2021 & 2027
Table 31: World Recent Past, Current & Future Analysis for Stem
Cell Banking by Geographic Region – USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets – Independent
Analysis of Annual Sales in US$ Million for Years 2020 through
2027 and % CAGR
Table 32: World Historic Review for Stem Cell Banking by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets – Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR
Table 33: World 15-Year Perspective for Stem Cell Banking by
Geographic Region – Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2021 & 2027
Table 34: World Recent Past, Current & Future Analysis for
Tissue Engineering by Geographic Region – USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets –
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR
Table 35: World Historic Review for Tissue Engineering by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets – Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR
Table 36: World 15-Year Perspective for Tissue Engineering by
Geographic Region – Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2021 & 2027
Table 37: World Recent Past, Current & Future Analysis for
Toxicology Studies by Geographic Region – USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets –
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR
Table 38: World Historic Review for Toxicology Studies by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets – Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR
Table 39: World 15-Year Perspective for Toxicology Studies by
Geographic Region – Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2021 & 2027
Table 40: World Mesenchymal Stem Cells (MSC) Market Analysis of
Annual Sales in US$ Million for Years 2012 through 2027
III. MARKET ANALYSIS
UNITED STATES
Mesenchymal Stem Cells (MSC) Market Presence – Strong/Active/
Niche/Trivial – Key Competitors in the United States for 2022
(E)
Table 41: USA Recent Past, Current & Future Analysis for
Mesenchymal Stem Cells (MSC) by Application – Disease
Modelling, Drug Development & Discovery, Stem Cell Banking,
Tissue Engineering, Toxicology Studies and Other Applications –
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR
Table 42: USA Historic Review for Mesenchymal Stem Cells (MSC)
by Application – Disease Modelling, Drug Development &
Discovery, Stem Cell Banking, Tissue Engineering, Toxicology
Studies and Other Applications Markets – Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR
Table 43: USA 15-Year Perspective for Mesenchymal Stem Cells
(MSC) by Application – Percentage Breakdown of Value Sales for
Disease Modelling, Drug Development & Discovery, Stem Cell
Banking, Tissue Engineering, Toxicology Studies and Other
Applications for the Years 2012, 2021 & 2027
Table 44: USA Recent Past, Current & Future Analysis for
Mesenchymal Stem Cells (MSC) by Source of MSC Isolation – Bone
Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and
Other Sources of MSC Isolation – Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 45: USA Historic Review for Mesenchymal Stem Cells (MSC)
by Source of MSC Isolation – Bone Marrow, Adipose Tissues,
Fetal Liver, Lung, Cord Blood and Other Sources of MSC
Isolation Markets – Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR
Table 46: USA 15-Year Perspective for Mesenchymal Stem Cells
(MSC) by Source of MSC Isolation – Percentage Breakdown of
Value Sales for Bone Marrow, Adipose Tissues, Fetal Liver,
Lung, Cord Blood and Other Sources of MSC Isolation for the
Years 2012, 2021 & 2027
CANADA
Table 47: Canada Recent Past, Current & Future Analysis for
Mesenchymal Stem Cells (MSC) by Application – Disease
Modelling, Drug Development & Discovery, Stem Cell Banking,
Tissue Engineering, Toxicology Studies and Other Applications –
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR
Table 48: Canada Historic Review for Mesenchymal Stem Cells
(MSC) by Application – Disease Modelling, Drug Development &
Discovery, Stem Cell Banking, Tissue Engineering, Toxicology
Studies and Other Applications Markets – Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR
Table 49: Canada 15-Year Perspective for Mesenchymal Stem Cells
(MSC) by Application – Percentage Breakdown of Value Sales for
Disease Modelling, Drug Development & Discovery, Stem Cell
Banking, Tissue Engineering, Toxicology Studies and Other
Applications for the Years 2012, 2021 & 2027
Table 50: Canada Recent Past, Current & Future Analysis for
Mesenchymal Stem Cells (MSC) by Source of MSC Isolation – Bone
Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and
Other Sources of MSC Isolation – Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 51: Canada Historic Review for Mesenchymal Stem Cells
(MSC) by Source of MSC Isolation – Bone Marrow, Adipose
Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC
Isolation Markets – Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR
Table 52: Canada 15-Year Perspective for Mesenchymal Stem Cells
(MSC) by Source of MSC Isolation – Percentage Breakdown of
Value Sales for Bone Marrow, Adipose Tissues, Fetal Liver,
Lung, Cord Blood and Other Sources of MSC Isolation for the
Years 2012, 2021 & 2027
JAPAN
Mesenchymal Stem Cells (MSC) Market Presence – Strong/Active/
Niche/Trivial – Key Competitors in Japan for 2022 (E)
Table 53: Japan Recent Past, Current & Future Analysis for
Mesenchymal Stem Cells (MSC) by Application – Disease
Modelling, Drug Development & Discovery, Stem Cell Banking,
Tissue Engineering, Toxicology Studies and Other Applications –
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR
Table 54: Japan Historic Review for Mesenchymal Stem Cells
(MSC) by Application – Disease Modelling, Drug Development &
Discovery, Stem Cell Banking, Tissue Engineering, Toxicology
Studies and Other Applications Markets – Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR
Table 55: Japan 15-Year Perspective for Mesenchymal Stem Cells
(MSC) by Application – Percentage Breakdown of Value Sales for
Disease Modelling, Drug Development & Discovery, Stem Cell
Banking, Tissue Engineering, Toxicology Studies and Other
Applications for the Years 2012, 2021 & 2027
Table 56: Japan Recent Past, Current & Future Analysis for
Mesenchymal Stem Cells (MSC) by Source of MSC Isolation – Bone
Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and
Other Sources of MSC Isolation – Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 57: Japan Historic Review for Mesenchymal Stem Cells
(MSC) by Source of MSC Isolation – Bone Marrow, Adipose
Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC
Isolation Markets – Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR
Table 58: Japan 15-Year Perspective for Mesenchymal Stem Cells
(MSC) by Source of MSC Isolation – Percentage Breakdown of
Value Sales for Bone Marrow, Adipose Tissues, Fetal Liver,
Lung, Cord Blood and Other Sources of MSC Isolation for the
Years 2012, 2021 & 2027
CHINA
Mesenchymal Stem Cells (MSC) Market Presence – Strong/Active/
Niche/Trivial – Key Competitors in China for 2022 (E)
Table 59: China Recent Past, Current & Future Analysis for
Mesenchymal Stem Cells (MSC) by Application – Disease
Modelling, Drug Development & Discovery, Stem Cell Banking,
Tissue Engineering, Toxicology Studies and Other Applications –
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR
Table 60: China Historic Review for Mesenchymal Stem Cells
(MSC) by Application – Disease Modelling, Drug Development &
Discovery, Stem Cell Banking, Tissue Engineering, Toxicology
Studies and Other Applications Markets – Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR
Table 61: China 15-Year Perspective for Mesenchymal Stem Cells
(MSC) by Application – Percentage Breakdown of Value Sales for
Disease Modelling, Drug Development & Discovery, Stem Cell
Banking, Tissue Engineering, Toxicology Studies and Other
Applications for the Years 2012, 2021 & 2027
Table 62: China Recent Past, Current & Future Analysis for
Mesenchymal Stem Cells (MSC) by Source of MSC Isolation – Bone
Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and
Other Sources of MSC Isolation – Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 63: China Historic Review for Mesenchymal Stem Cells
(MSC) by Source of MSC Isolation – Bone Marrow, Adipose
Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC
Isolation Markets – Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR
Table 64: China 15-Year Perspective for Mesenchymal Stem Cells
(MSC) by Source of MSC Isolation – Percentage Breakdown of
Value Sales for Bone Marrow, Adipose Tissues, Fetal Liver,
Lung, Cord Blood and Other Sources of MSC Isolation for the
Years 2012, 2021 & 2027
EUROPE
Mesenchymal Stem Cells (MSC) Market Presence – Strong/Active/
Niche/Trivial – Key Competitors in Europe for 2022 (E)
Table 65: Europe Recent Past, Current & Future Analysis for
Mesenchymal Stem Cells (MSC) by Application – Disease
Modelling, Drug Development & Discovery, Stem Cell Banking,
Tissue Engineering, Toxicology Studies and Other Applications –
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR
Table 66: Europe Historic Review for Mesenchymal Stem Cells
(MSC) by Application – Disease Modelling, Drug Development &
Discovery, Stem Cell Banking, Tissue Engineering, Toxicology
Studies and Other Applications Markets – Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR
Table 67: Europe 15-Year Perspective for Mesenchymal Stem Cells
(MSC) by Application – Percentage Breakdown of Value Sales for
Disease Modelling, Drug Development & Discovery, Stem Cell
Banking, Tissue Engineering, Toxicology Studies and Other
Applications for the Years 2012, 2021 & 2027
Table 68: Europe Recent Past, Current & Future Analysis for
Mesenchymal Stem Cells (MSC) by Geographic Region – France,
Germany, Italy, UK and Rest of Europe Markets – Independent
Analysis of Annual Sales in US$ Million for Years 2020 through
2027 and % CAGR
Table 69: Europe Historic Review for Mesenchymal Stem Cells
(MSC) by Geographic Region – France, Germany, Italy, UK and
Rest of Europe Markets – Independent Analysis of Annual Sales
in US$ Million for Years 2012 through 2019 and % CAGR
Table 70: Europe 15-Year Perspective for Mesenchymal Stem Cells
(MSC) by Geographic Region – Percentage Breakdown of Value
Sales for France, Germany, Italy, UK and Rest of Europe Markets
for Years 2012, 2021 & 2027
Table 71: Europe Recent Past, Current & Future Analysis for
Mesenchymal Stem Cells (MSC) by Source of MSC Isolation – Bone
Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and
Other Sources of MSC Isolation – Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 72: Europe Historic Review for Mesenchymal Stem Cells
(MSC) by Source of MSC Isolation – Bone Marrow, Adipose
Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC
Isolation Markets – Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR
Table 73: Europe 15-Year Perspective for Mesenchymal Stem Cells
(MSC) by Source of MSC Isolation – Percentage Breakdown of
Value Sales for Bone Marrow, Adipose Tissues, Fetal Liver,
Lung, Cord Blood and Other Sources of MSC Isolation for the
Years 2012, 2021 & 2027
FRANCE
Mesenchymal Stem Cells (MSC) Market Presence – Strong/Active/
Niche/Trivial – Key Competitors in France for 2022 (E)
Table 74: France Recent Past, Current & Future Analysis for
Mesenchymal Stem Cells (MSC) by Application – Disease
Modelling, Drug Development & Discovery, Stem Cell Banking,
Tissue Engineering, Toxicology Studies and Other Applications –
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR
Table 75: France Historic Review for Mesenchymal Stem Cells
(MSC) by Application – Disease Modelling, Drug Development &
Discovery, Stem Cell Banking, Tissue Engineering, Toxicology
Studies and Other Applications Markets – Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR
Table 76: France 15-Year Perspective for Mesenchymal Stem Cells
(MSC) by Application – Percentage Breakdown of Value Sales for
Disease Modelling, Drug Development & Discovery, Stem Cell
Banking, Tissue Engineering, Toxicology Studies and Other
Applications for the Years 2012, 2021 & 2027
Table 77: France Recent Past, Current & Future Analysis for
Mesenchymal Stem Cells (MSC) by Source of MSC Isolation – Bone
Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and
Other Sources of MSC Isolation – Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 78: France Historic Review for Mesenchymal Stem Cells
(MSC) by Source of MSC Isolation – Bone Marrow, Adipose
Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC
Isolation Markets – Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR
Table 79: France 15-Year Perspective for Mesenchymal Stem Cells
(MSC) by Source of MSC Isolation – Percentage Breakdown of
Value Sales for Bone Marrow, Adipose Tissues, Fetal Liver,
Lung, Cord Blood and Other Sources of MSC Isolation for the
Years 2012, 2021 & 2027
GERMANY
Mesenchymal Stem Cells (MSC) Market Presence – Strong/Active/
Niche/Trivial – Key Competitors in Germany for 2022 (E)
Table 80: Germany Recent Past, Current & Future Analysis for
Mesenchymal Stem Cells (MSC) by Application – Disease
Modelling, Drug Development & Discovery, Stem Cell Banking,
Tissue Engineering, Toxicology Studies and Other Applications –
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR
Table 81: Germany Historic Review for Mesenchymal Stem Cells
(MSC) by Application – Disease Modelling, Drug Development &
Discovery, Stem Cell Banking, Tissue Engineering, Toxicology
Studies and Other Applications Markets – Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR
Table 82: Germany 15-Year Perspective for Mesenchymal Stem
Cells (MSC) by Application – Percentage Breakdown of Value
Sales for Disease Modelling, Drug Development & Discovery, Stem
Cell Banking, Tissue Engineering, Toxicology Studies and Other
Applications for the Years 2012, 2021 & 2027
Table 83: Germany Recent Past, Current & Future Analysis for
Mesenchymal Stem Cells (MSC) by Source of MSC Isolation – Bone
Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and
Other Sources of MSC Isolation – Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 84: Germany Historic Review for Mesenchymal Stem Cells
(MSC) by Source of MSC Isolation – Bone Marrow, Adipose
Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC
Isolation Markets – Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR
Table 85: Germany 15-Year Perspective for Mesenchymal Stem
Cells (MSC) by Source of MSC Isolation – Percentage Breakdown
of Value Sales for Bone Marrow, Adipose Tissues, Fetal Liver,
Lung, Cord Blood and Other Sources of MSC Isolation for the
Years 2012, 2021 & 2027
ITALY
Table 86: Italy Recent Past, Current & Future Analysis for
Mesenchymal Stem Cells (MSC) by Application – Disease
Modelling, Drug Development & Discovery, Stem Cell Banking,
Tissue Engineering, Toxicology Studies and Other Applications –
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR
Table 87: Italy Historic Review for Mesenchymal Stem Cells
(MSC) by Application – Disease Modelling, Drug Development &
Discovery, Stem Cell Banking, Tissue Engineering, Toxicology
Studies and Other Applications Markets – Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR
Table 88: Italy 15-Year Perspective for Mesenchymal Stem Cells
(MSC) by Application – Percentage Breakdown of Value Sales for
Disease Modelling, Drug Development & Discovery, Stem Cell
Banking, Tissue Engineering, Toxicology Studies and Other
Applications for the Years 2012, 2021 & 2027
Table 89: Italy Recent Past, Current & Future Analysis for
Mesenchymal Stem Cells (MSC) by Source of MSC Isolation – Bone
Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and
Other Sources of MSC Isolation – Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 90: Italy Historic Review for Mesenchymal Stem Cells
(MSC) by Source of MSC Isolation – Bone Marrow, Adipose
Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC
Isolation Markets – Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR
Table 91: Italy 15-Year Perspective for Mesenchymal Stem Cells
(MSC) by Source of MSC Isolation – Percentage Breakdown of
Value Sales for Bone Marrow, Adipose Tissues, Fetal Liver,
Lung, Cord Blood and Other Sources of MSC Isolation for the
Years 2012, 2021 & 2027
UNITED KINGDOM
Mesenchymal Stem Cells (MSC) Market Presence – Strong/Active/
Niche/Trivial – Key Competitors in the United Kingdom for 2022
(E)
Table 92: UK Recent Past, Current & Future Analysis for
Mesenchymal Stem Cells (MSC) by Application – Disease
Modelling, Drug Development & Discovery, Stem Cell Banking,
Tissue Engineering, Toxicology Studies and Other Applications –
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR
Table 93: UK Historic Review for Mesenchymal Stem Cells (MSC)
by Application – Disease Modelling, Drug Development &
Discovery, Stem Cell Banking, Tissue Engineering, Toxicology
Studies and Other Applications Markets – Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR
Table 94: UK 15-Year Perspective for Mesenchymal Stem Cells
(MSC) by Application – Percentage Breakdown of Value Sales for
Disease Modelling, Drug Development & Discovery, Stem Cell
Banking, Tissue Engineering, Toxicology Studies and Other
Applications for the Years 2012, 2021 & 2027
Table 95: UK Recent Past, Current & Future Analysis for
Mesenchymal Stem Cells (MSC) by Source of MSC Isolation – Bone
Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and
Other Sources of MSC Isolation – Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Table 96: UK Historic Review for Mesenchymal Stem Cells (MSC)
by Source of MSC Isolation – Bone Marrow, Adipose Tissues,
Fetal Liver, Lung, Cord Blood and Other Sources of MSC
Isolation Markets – Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR
Table 97: UK 15-Year Perspective for Mesenchymal Stem Cells
(MSC) by Source of MSC Isolation – Percentage Breakdown of
Value Sales for Bone Marrow, Adipose Tissues, Fetal Liver,
Lung, Cord Blood and Other Sources of MSC Isolation for the
Years 2012, 2021 & 2027
REST OF EUROPE
Table 98: Rest of Europe Recent Past, Current & Future Analysis
for Mesenchymal Stem Cells (MSC) by Application – Disease
Modelling, Drug Development & Discovery, Stem Cell Banking,
Tissue Engineering, Toxicology Studies and Other Applications –
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR
Table 99: Rest of Europe Historic Review for Mesenchymal Stem
Cells (MSC) by Application – Disease Modelling, Drug
Development & Discovery, Stem Cell Banking, Tissue Engineering,
Toxicology Studies and Other Applications Markets – Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR
Table 100: Rest of Europe 15-Year Perspective for Mesenchymal
Stem Cells (MSC) by Application – Percentage Breakdown of Value
Sales for Disease Modelling, Drug Development & Discovery, Stem
Cell Banking, Tissue Engineering, Toxicology Studies and Other
Applications for the Years 2012, 2021 & 2027
Table 101: Rest of Europe Recent Past, Current & Future
Analysis for Mesenchymal Stem Cells (MSC) by Source of MSC
Isolation – Bone Marrow, Adipose Tissues, Fetal Liver, Lung,
Cord Blood and Other Sources of MSC Isolation – Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR
Table 102: Rest of Europe Historic Review for Mesenchymal Stem
Cells (MSC) by Source of MSC Isolation – Bone Marrow, Adipose
Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC
Isolation Markets – Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR
Table 103: Rest of Europe 15-Year Perspective for Mesenchymal
Stem Cells (MSC) by Source of MSC Isolation – Percentage
Please contact our Customer Support Center to get the complete Table of Contents
Read the full report: https://www.reportlinker.com/p05961465/?utm_source=GNW
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.
__________________________
Contact Data
Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001